Results 181 to 190 of about 18,455 (220)

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

Seminars in Nuclear Medicine, 2020
Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important modality in the therapeutic armamentarium of advanced, metastatic or inoperable, progressive Neuroendocrine Neoplasms (NENs). This review deliberates on the basic understanding and applied clinical aspects of PRRT in NENs, with special reference to (1) tumor ...
Sandip, Basu, Rahul V, Parghane, , Kamaldeep, Sudipta, Chakrabarty   +3 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy: An Overview

Cancer Biotherapy and Radiopharmaceuticals, 2015
Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors.
Ashutosh, Dash, Sudipta, Chakraborty, Maroor Raghavan Ambikalmajan, Pillai, Furn F Russ, Knapp   +3 more
openaire   +2 more sources

Peptide-receptor radionuclide therapy for endocrine tumors

Nature Reviews Endocrinology, 2009
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors. Treatment with somatostatin analogs labeled with (111)In, (90)Y or (177)Lu can result in symptomatic improvement, although tumor remission is seldom achieved with (111)In-labeled
Essen, Martijn, Krenning, Eric, Kam, BLR, Jong, Marion, Valkema, R., Kwekkeboom, Dik   +5 more
openaire   +3 more sources

Peptide Receptor Radionuclide Therapy: Preclinical Findings

2016
Somatostatin is a cyclopeptide that has a broad inhibitory effect on the secretion of hormones such as growth hormone, glucagon, and insulin. The molecular basis of the use of radiolabeled octreotide in scintigraphy and radionuclide therapy is receptor-mediated internalization and cellular retention of the radionuclide.
Capello, A (Astrid), Breeman, Wout, Bernard, HF, Jong, Marion, Krenning, Eric   +4 more
openaire   +2 more sources

Peptide receptor radionuclide therapy of neuroendocrine tumours

Best Practice & Research Clinical Endocrinology & Metabolism, 2016
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177 ...
Brabander, Tessa, Teunissen, Jaap, van Eijck, Casper, Franssen, Gaston, Feelders, R.A., de Herder, W.W., Kwekkeboom, Dik   +6 more
openaire   +2 more sources

Renal Dosimetry in Peptide Radionuclide Receptor Therapy

Cancer Biotherapy and Radiopharmaceuticals, 2010
Abstract This study evaluates the predictive value of absorbed dose, biological effective dose, and time-dose-fractionation factors for use in patients receiving peptide radionuclide receptor therapy treatments by reanalyzing data in two different patient populations that have been reported in the literature. The analysis suggested that the alternative
Jeffry A, Siegel, Michael G, Stabin, Robert M, Sharkey   +2 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy (PRRT)

2016
There has been tremendous progress over recent years on the development of peptide receptor radionuclide therapy (PRRT) for the treatment of a variety of cancers. In this technology, peptides radiolabeled with therapeutic radionuclides are targeted to cell-surface receptors which are often overexpressed on the membrane surface of tumor cells.
F. F. Knapp, Ashutosh Dash
openaire   +1 more source

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

2015
Peptide receptor radionuclide therapy (PRRT) has been a well-accepted and effective therapeutic modality for inoperable or metastatic gastroenteropancreatic, bronchopulmonary and other neuroendocrine tumors for almost 2 decades. In general, PRRT is well tolerated with moderate toxicity in the majority of patients if the necessary precautions ...
Lisa, Bodei, Mark, Kidd, Vikas, Prasad, Irvin M, Modlin   +3 more
openaire   +2 more sources

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Best Practice & Research Clinical Gastroenterology, 2012
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15 ...
Bergsma, Hendrik, Vliet, Esther, Teunissen, Jaap, Kam, BLR, de Herder, W.W., Peeters, Robin, Krenning, Eric, Kwekkeboom, Dik   +7 more
openaire   +3 more sources

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

Current Radiopharmaceuticals, 2019
Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management.
Shahad, Alsadik, Siraj, Yusuf, Adil, Al-Nahhas   +2 more
openaire   +2 more sources